This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Learn About Coagulation Disorders
-What are Bleeding Disorders?
 History of Bleeding Disorders
-Types of Bleeding Disorders
 Hemophilia A
 Hemophilia B
 von Willebrand Disease
-Other Factor Deficiencies
-Factor I
 Factor II
 Factor V
 Factor VII
 Factor X
 Factor XI
 Factor XII
 Factor XIII
 Types of Bleeds
 Bleeding Disorders and Women
 Caring for the Newly Diagnosed Child
 Psychosocial Issues
 Complications, including Inhibitors
 Future Therapies
 What are Clotting Disorders?
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Medical and Scientific Advisory Council
 Financial and Insurance Issues
 HANDI, NHF's Information Resource Center
 Web Links



Factor I Deficiency

(can also be known as Fibrinogen deficiency, afibrinogenemia, dysfibrinogenemia, or hypofibrinogenemia)

Factor I deficiency is actually a collective term for several rare inherited fibrinogen deficiencies.  Fibrinogen may be absent from the blood altogether (afibrinogenemia), present in only very low levels in the blood (hypofibrinogenemia), or measurable in normal quantities but defective (dysfibrinogenemia). 

The incidence of Factor I deficiency is estimated at 1 to 2 per million.  It is inherited in an autosomal recessive fashion, which means it affects men and women equally.  

Fibrinogen helps platelets to glue together to form the initial “plug” in response to an injury.  Therefore, people with factor I deficiency, have a combined bleeding disorder because both platelets and clotting are abnormal.  The severity of the disorder is directly related to the amount of fibrinogen present. 

Afibrinogenemia and hypofibrogenemia are usually diagnosed in newborns who can present with head bleeds, bleeding after circumcision and from the site of the umbilical cord.  Easy bruising, nose and mouth bleeds, and soft tissue bleeds are also common.  Joint bleeding is relatively uncommon.  Women with afibinogenemia have an increased risk of spontaneous abortion.  Persons with dysfibrinogenemia may have a disposition to thrombosis.    

Diagnosis is made by measuring the amount of fibrinogen in the blood, prothrombin time (PT) test, activated partial thromboplastin time (aPTT) test, and thrombin clotting time (TCT) test. 


For now, cryoprecipitate is the treatment of choice in the United States.  FFP may be given, but cryoprecipitate is used more often to avoid volume overload.  There are no Factor I concentrates available for use in the U.S.  However, there are three fibrinogen concentrates being used in Europe and Japan.  There have also been some reports of adverse reactions with use of these concentrates.   


This section of our Web site is sponsored by: